logo

Alexion Pharmaceuticals Inc. (ALXN)



Trade ALXN now with
  Date
  Headline
4/11/2018 1:58:50 AM Alexion Announces Recommended Public Cash Offer To Wilson Therapeutics
3/15/2018 6:32:51 AM Alexion Reports Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210
2/9/2018 7:45:40 AM RBC Capital Markets Is Lowering Alexion Pharmaceuticals Inc. (ALXN) FY19 Rev. Estimate To 4.64 Billion From 4.70 Billion
2/9/2018 7:45:27 AM RBC Capital Markets Is Increasing Alexion Pharmaceuticals Inc. (ALXN) FY18 Rev. Estimate To 3.92 Billion From 3.91 Billion
2/9/2018 7:44:59 AM RBC Capital Markets Is Increasing Alexion Pharmaceuticals Inc. (ALXN) FY19 Estimate To 5.11 From 4.67
2/9/2018 7:44:49 AM RBC Capital Markets Is Increasing Alexion Pharmaceuticals Inc. (ALXN) FY18 Estimate To 3.98 From 3.03
2/8/2018 6:31:16 AM Alexion 2017 Total Revenues $3.551 Bln, Up 15%
2/6/2018 7:34:26 PM Alexion Pharma Reports Combined Interim Data From Two Ongoing Open-label Studies, VITAL And CL-08
2/5/2018 4:05:33 PM Alexion Appoints Judith Reinsdorf To Its Board Of Directors
1/22/2018 4:06:44 PM Alexion Appoints Deborah Dunsire To Its Board Of Directors
12/26/2017 6:31:28 AM Alexion : Soliris Gets Marketing Authorization In Japan For Treatment Of Patients With Generalized Myasthenia Gravis
12/11/2017 10:02:09 AM Alexion Announces Presentation Of Comprehensive Dose-ranging Data From Two Phase 1b/2 Studies Of ALXN1210